NCT05001516: Study of LaNova Medicines (LM-302) in Patients With Advance Solid Tumors

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Breast cancer patients are not eligible for phase 1b (dose expansion) of the study
Exclusions: Patients with known central nervous system (CNS) or leptomeningeal metastasis

Comments are closed.

Up ↑